CB2 Insights Inc. (CSE:CBII,Forum) announced on Thursday that it has been selected by Drug Science as the exclusive research technology platform for the UK's largest medical cannabis pilot project - TWENTY21. The project aims to enroll 20,000 patients and CB2 will build the patient registry and generate real-world evidence throughout the program.
For more on this, click here.
CB2 recentlystated that Phase One of its Clinical Decision Support tool integration has been successfully completed via Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) and its Electronic Medical Records platform, Juno, which provides access to its over 4,600 primary care physician and healthcare practitioner users. The platform is intended to guide clinicians through the evaluation process for medical cannabis treatment.
FULL DISCLOSURE: CB2 Insights Inc. is a client of Stockhouse Publishing.